Arkolith/Insider Trading/NBY/Form 4

Kazley Michael John

Chief Executive Officer, Director, 10% OwnerNovaBay Pharmaceuticals, Inc. (NBY) · full profile →Form 4 · filed Nov 3, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 21, 2025Conversion(C)56.8M—$056.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 16, 2025Buy(P)2.7M—$02.7M

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-032854) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML